Coadministered cannabidiol and clobazam: Preclinical evidence for both pharmacodynamic and pharmacokinetic interactions

OBJECTIVE: Cannabidiol (CBD) has been approved by the US Food and Drug Administration (FDA) to treat intractable childhood epilepsies, such as Dravet syndrome and Lennox‐Gastaut syndrome. However, the intrinsic anticonvulsant activity of CBD has been questioned due to a pharmacokinetic interaction b...

Descripción completa

Detalles Bibliográficos
Autores principales: Anderson, Lyndsey L., Absalom, Nathan L., Abelev, Sarah V., Low, Ivan K., Doohan, Peter T., Martin, Lewis J., Chebib, Mary, McGregor, Iain S., Arnold, Jonathon C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Full‐length Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6900043/
https://www.ncbi.nlm.nih.gov/pubmed/31625159
http://dx.doi.org/10.1111/epi.16355

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6900043/
https://www.ncbi.nlm.nih.gov/pubmed/31625159
http://dx.doi.org/10.1111/epi.16355

Ejemplares similares